- Home
- CNOBP vs LYEL Comparison
CNOBP vs LYEL Comparison
Compare CNOBP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOBP
- LYEL
- Stock Information
- Founded
- CNOBP N/A
- LYEL 2018
- Country
- CNOBP United States
- LYEL United States
- Employees
- CNOBP 493
- LYEL N/A
- Industry
- CNOBP Major Banks
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CNOBP Finance
- LYEL Health Care
- Exchange
- CNOBP Nasdaq
- LYEL Nasdaq
- Market Cap
- CNOBP N/A
- LYEL 207.7M
- IPO Year
- CNOBP N/A
- LYEL 2021
- Fundamental
- Price
- CNOBP $22.94
- LYEL $9.43
- Analyst Decision
- CNOBP
- LYEL Sell
- Analyst Count
- CNOBP 0
- LYEL 2
- Target Price
- CNOBP N/A
- LYEL $15.00
- AVG Volume (30 Days)
- CNOBP N/A
- LYEL 311.0K
- Earning Date
- CNOBP N/A
- LYEL 08-06-2025
- Dividend Yield
- CNOBP N/A
- LYEL N/A
- EPS Growth
- CNOBP N/A
- LYEL N/A
- EPS
- CNOBP N/A
- LYEL N/A
- Revenue
- CNOBP N/A
- LYEL $65,000.00
- Revenue This Year
- CNOBP N/A
- LYEL N/A
- Revenue Next Year
- CNOBP N/A
- LYEL N/A
- P/E Ratio
- CNOBP N/A
- LYEL N/A
- Revenue Growth
- CNOBP N/A
- LYEL N/A
- 52 Week Low
- CNOBP N/A
- LYEL $7.65
- 52 Week High
- CNOBP N/A
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- CNOBP 57.29
- LYEL 50.01
- Support Level
- CNOBP $22.61
- LYEL $8.46
- Resistance Level
- CNOBP $23.08
- LYEL $9.80
- Average True Range (ATR)
- CNOBP 0.10
- LYEL 0.90
- MACD
- CNOBP -0.01
- LYEL -0.09
- Stochastic Oscillator
- CNOBP 70.55
- LYEL 38.80
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.